Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Roche Holding AG

SwitzerlandAdoptersAssignment FullData quality High

Key messagelimited AI Footprint

Roche uses artificial intelligence mainly in diagnostic products such as digital pathology and the assessment of kidney risk as well as in research, and has adopted its own ethical principles for this. On security there is an external certification of information security, a public channel for reporting vulnerabilities and regulatory reviews of individual products, while board oversight of AI and precise information on the data and limits of the AI models were not found.

Opportunities

  • Safetysolid

    For the digital pathology platform there is an FDA 510(k) clearance with a published clinical study (S16, A); it concerns the imaging system, not the AI algorithms.

    For the digital pathology platform there is an FDA 510(k) clearance with a published clinical study (S16, A); it concerns the imaging system, not the AI algorithms. The Kidney Klinrisk algorithm carries an IVDR marking by a notified body and has been validated in a peer-reviewed study (S18, S32, B). The navify platform is certified to ISO/IEC 27001:2022 by BSI (S28, B), and Roche operates coordinated vulnerability disclosure with dated CVE advisories, including on AI platform components (S22, B). Counter-evidence includes an open FDA recall of the navify pathology software due to misassigned images (S24, minor, without AI link) and a high-severity vulnerability involving default credentials in the same software; AI-specific testing, red-teaming and monitoring in operation are not documented, hence not “strong”.

Risks

  • Responsibilitylimited

    Roche has its own AI ethics principles, adopted by the Corporate Executive Committee on 2023-12-20 and updated in 2025, supplemented by data ethics principles and an AI clause in the code of conduct (S01, S30, S29).

    Roche has its own AI ethics principles, adopted by the Corporate Executive Committee on 2023-12-20 and updated in 2025, supplemented by data ethics principles and an AI clause in the code of conduct (S01, S30, S29). The terms of reference of the board committees mention neither AI nor data nor cybersecurity (S10, B); an AI governance function and a framework for AI risks are documented only by an interview with the head of digital (S12). Concrete AI metrics, external audits or certifications of an AI management system are missing, and the scope of the KPMG assurance does not cover AI (S41). Only grade C evidence therefore supports an approach; the corporate governance section of the annual report was not readable.

  • Transparencylimited

    The AI principles commit to disclosing AI-enabled product features and documenting assumptions, limitations and data sources (S01, C), and product pages label algorithms as AI- or ML-based with regulatory status and intended purpose (S40, S18, C).

    The AI principles commit to disclosing AI-enabled product features and documenting assumptions, limitations and data sources (S01, C), and product pages label algorithms as AI- or ML-based with regulatory status and intended purpose (S40, S18, C). The only grade B source on model performance is the peer-reviewed validation of the Klinrisk model, which was developed by KlinRisk Inc. and is only distributed by Roche (S32). Model or system cards, information on training data and transparency reports on Roche's own algorithms were not found. This is not enough for “solid”.

  • Risk area

    Diagnostic AI influencing clinical decisions, for example in pathology

  • Risk area

    Prediction algorithms in diabetes care

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
43searches
42pages and documents read
12primary documents
2controversies checked
6open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Roche Holding AGOverall rating: limited

Roche uses AI mainly in diagnostic products and documents certification, regulatory reviews and a channel for reporting vulnerabilities. Board oversight of AI and precise information on the data and limits of its algorithms are missing.

Responsibility

40 %
limitedsolidstrong

Roche has its own AI ethics principles, but AI oversight by the board is not documented.

  • +AI ethics principles adopted by executive management Source ↗
  • +Code of conduct requires approval of new third-party tools Source ↗
  • –Board committees name no responsibility for AI Source ↗
  • –AI governance function documented only in an interview Source ↗
  • –External assurance by KPMG covers no AI metrics Source ↗
All sources for this pillar (11)

Safety

40 %
limitedsolidstrong

Certified platform and regulatory reviews, but AI-specific testing is not documented.

  • +FDA clearance of the pathology platform with a clinical study Source ↗
  • +navify platform certified to ISO/IEC 27001:2022 Source ↗
  • +Public reporting channel and dated vulnerability advisories Source ↗
  • –Open FDA recall of the navify pathology software Source ↗
  • –AI-specific testing and monitoring in operation not documented
All sources for this pillar (19)

Transparency

20 %
limitedsolidstrong

AI features are labelled, but information on data and limitations is missing.

  • +Product pages label AI features and regulatory status Source ↗
  • +Principles commit to disclosing limitations and data sources Source ↗
  • –No model or system documentation for Roche's own algorithms
  • –The only peer-reviewed performance study concerns a partner model Source ↗
All sources for this pillar (6)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
Anchor AI oversight in the board

Assign responsibility for AI to a board committee and publish a procedure for risk classification and approval of AI.

2Safety
Test AI algorithms verifiably

Publish validation and monitoring data for Roche's own AI algorithms in pathology and diabetes.

3Transparency
Document data and limitations

Disclose training data, performance limits and error rates for each of Roche's own algorithms in product documentation.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← Roche Holding AG is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
2 2 minor

No deduction for controversies.

Largest risk area
Misclassification by diagnostic AI

Diagnostic algorithms in pathology and kidney risk influence clinical decisions, yet validation and monitoring data for Roche's own AI were not found.

How thoroughly assessed
36 Evidence

12 primary documents read, 43 searches.

Read the full reasoning and all sources
Roche Holding AG · Full reasoning

Tested diagnostic platforms, but no documented AI oversight at board level

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

Executive management has adopted AI ethics principles, but the board committees mention neither AI nor data nor cybersecurity.

What is documented
  • Executive management adopted the AI ethics principles on 20 December 2023 and updated them in 20251
  • The principles require accountability across the entire life cycle, including third-party systems, and human oversight1
  • Data ethics principles and an AI clause in the code of conduct supplement the AI principles11 6
  • The Chief Digital and Technology Officer has been a member of the enlarged Corporate Executive Committee since 20252 3
  • Speak-up channels via an external provider allow anonymous reports and escalate up to board committees6
The case against
Oversight not documented
  • The terms of reference of the four board committees contain no responsibility for AI, data or cyber5
  • The AI governance function and a framework for AI risks are documented only by an interview with the head of digital4
  • The corporate governance section of the 2025 annual report was not readable
Governance and accountability
  • A risk classification of AI applications and an AI approval procedure are not documented1 7
  • The external assurance by KPMG covers no AI, data or cyber metrics9
  • AI metrics and a certification of an AI management system were not found
Sources for Responsibility (11)
  1. F. Hoffmann-La Roche Ltd: Roche Artificial Intelligence (AI) Ethics Principles · 1 April 2025 · secondary source
  2. Roche Holding AG: Annual Report 2025 (English) · 29 January 2026 · secondary source
  3. Roche Holding AG: Wafaa Mamilli (leadership profile) · 3 November 2026 · secondary source
  4. CIO.com (Martha Heller): How Roche drives AI outcomes in a changing world (interview with Wafaa Mamilli) · 16 September 2026 · secondary source
  5. Roche Holding AG: Board Committees (website) · 3 November 2026 · primary source
  6. F. Hoffmann-La Roche Ltd, Group Legal Compliance: Roche Group Code of Conduct (© 2025) · 3 November 2026 · secondary source
  7. Roche Holding AG: Risk and opportunity management (website) · 3 November 2026 · secondary source
  8. Built In London (Roche job advertisement): Senior Procurement AI Governance Manager · 17 August 2026 · secondary source
  9. KPMG AG: Independent assurance report on selected sustainability information 2025 · 27 January 2026 · primary source
  10. Roche Holding AG: Roche Annual General Meeting 2026 (media release) · 10 March 2026 · primary source
  11. F. Hoffmann-La Roche Ltd: Roche Data Ethics Principles · 1 March 2025 · secondary source

2 · Safety

solidWeight 40%

Roche documents approvals, an ISO certification and coordinated vulnerability disclosure, while AI-specific testing is lacking and a recall remains open.

What is documented
  • Roche Digital Pathology Dx received FDA 510(k) clearance with an accuracy study; it covers the imaging system, not the AI algorithms1 2
  • The Kidney Klinrisk algorithm carries a CE marking under the IVDR and has been validated in a peer-reviewed study by the model developer3 4
  • BSI certified Roche Diagnostics International to ISO/IEC 27001:2022 for the navify platform, valid until June 202710
  • Roche cites further ISO standards and internal and external penetration testing11 12
  • Roche operates a public reporting channel for security researchers and publishes dated advisories, including on AI platform components14
The case against
Recall and vulnerabilities
  • The FDA classified a recall of the navify Digital Pathology 2.5 software as class 2 because images could be assigned to the wrong samples; it remains open15
  • navify Digital Pathology had a high-severity vulnerability due to shipped default credentials; a remediation advisory has been published14
Missing AI testing
  • The AI-supported TROP2 companion diagnostic has only an FDA breakthrough designation, not an approval5
  • No accuracy data for Accu-Chek SmartGuide was published in the material read6
  • Red-teaming, testing of generative AI and validation data for Roche's own algorithms were not found
Sources for Safety (19)
  1. U.S. Food and Drug Administration: 510(k) Summary K232879 – Roche Digital Pathology Dx (VENTANA DP 200) · 18 June 2024 · primary source
  2. Roche Diagnostics: Roche receives FDA clearance on its digital pathology solution for diagnostic use (media release) · 18 June 2024 · secondary source
  3. Roche Holding AG: Roche receives CE mark for AI-based Kidney Klinrisk Algorithm (media release) · 6 October 2025 · secondary source
  4. Tangri N. et al. (Clinical Kidney Journal, via CiteDrive): Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population · 1 January 2024 · primary source
  5. Fierce Biotech: Roche receives FDA breakthrough label for AI-powered lung cancer companion diagnostic test · 3 November 2026 · secondary source
  6. MedTech Dive: Roche CE mark CGM Accu-Chek SmartGuide · 10 July 2024 · secondary source
  7. Roche Diagnostics: Image analysis algorithms (digital pathology product page) · 3 November 2026 · secondary source
  8. U.S. Food and Drug Administration: Artificial Intelligence-Enabled Medical Devices (list) · 4 September 2026 · primary source
  9. Roche Holding AG: Annual Report 2025 (English) · 29 January 2026 · secondary source
  10. BSI Assurance UK Limited: ISO/IEC 27001:2022 certificate IS 806759 for Roche Diagnostics International Ltd · 20 September 2024 · primary source
  11. Roche Diagnostics (navify): Digital trust – Certifications (website) · 3 November 2026 · secondary source
  12. Roche Diagnostics (navify): Digital trust – Penetration testing (website) · 3 November 2026 · secondary source
  13. Roche Holding AG: Genentech and NVIDIA enter into strategic AI research collaboration (Investor Update) · 21 November 2023 · secondary source
  14. Roche Diagnostics: Product Security Advisory (website) · 30 June 2026 · primary source
  15. U.S. Food and Drug Administration: Class 2 Device Recall navify Digital Pathology (Z-2913-2026) · 7 August 2026 · primary source
  16. F. Hoffmann-La Roche Ltd: Roche Data Ethics Principles · 1 March 2025 · secondary source
  17. F. Hoffmann-La Roche Ltd: Roche Artificial Intelligence (AI) Ethics Principles · 1 April 2025 · secondary source
  18. Abington Cole + Ellery (law firm): Genentech (Cencora / Lash Group) Data Breach · 22 May 2024 · secondary source
  19. Board Cybersecurity (Incident Tracker): Genentech cybersecurity incident · 6 April 2026 · secondary source

3 · Transparency

limitedWeight 20%

Product pages label AI features and regulatory status, but model or system documentation and training data for Roche's own algorithms were not found.

What is documented
  • The AI principles commit to disclosing AI-enabled features and the role of humans and to documenting assumptions, limitations and data sources1
  • Product pages label Klinrisk as ML-based, SmartGuide as using AI-based predictions and state the regulatory status of the pathology algorithms2 3 4
  • The pathology algorithms are described as aids; reviewing the results remains the responsibility of the pathologist2
  • The data ethics principles call for information on the origin and quality of data6
The case against
Missing model information
  • Model or system cards, information on training data and transparency reports on Roche's own algorithms were not found
  • The only peer-reviewed performance study concerns the Klinrisk model, which KlinRisk Inc. developed and Roche only distributes5
Limits not described
  • For Klinrisk the target group and purpose are stated, but no limitations3
  • Performance limits, error rates and explanations of the predictions of SmartGuide and TROP2 are not documented
Sources for Transparency (6)
  1. F. Hoffmann-La Roche Ltd: Roche Artificial Intelligence (AI) Ethics Principles · 1 April 2025 · secondary source
  2. Roche Diagnostics: Image analysis algorithms (digital pathology product page) · 3 November 2026 · secondary source
  3. Roche Holding AG: Roche receives CE mark for AI-based Kidney Klinrisk Algorithm (media release) · 6 October 2025 · secondary source
  4. MedTech Dive: Roche CE mark CGM Accu-Chek SmartGuide · 10 July 2024 · secondary source
  5. Tangri N. et al. (Clinical Kidney Journal, via CiteDrive): Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population · 1 January 2024 · primary source
  6. F. Hoffmann-La Roche Ltd: Roche Data Ethics Principles · 1 March 2025 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: within the 36-month window no judgment, regulatory decision, fine or pattern of serious incidents involving Roche's AI systems was found. The FDA recalls concern software without an AI link.

5 · Controversies (2)

6 · What remains open

  • Board oversight of AI and cybersecurity; the corporate governance section was not readable
  • AI policy with risk classification and approval procedures for own and purchased AI
  • Validation, monitoring and performance data for Roche's own AI algorithms
  • Regulatory status of the TROP2 companion diagnostic and completion status of the PathAI acquisition at the reference date
  • Providers and controls of the generative AI used internally
  • Cause, extent and attribution of the 2024 Genentech data incident

7 · How it was assessed

Cut-off date: 3 November 2026 · 43 searches, 42 fetches.

Primary documents read (12)
  • Roche Annual Report 2025 (English, up to approx. p. 67) and Geschäftsbericht 2025 (German, pp. 1–43)
  • Roche Finance Report 2025 (up to p. 41)
  • Roche AI Ethics Principles (version 2025-04-01)
  • Roche Data Ethics Principles (version March 2025)
  • Roche Group Code of Conduct (© 2025, complete with read-more section)
  • Roche Board Committees and Risk and opportunity management (web pages)
  • KPMG Independent assurance report 2025
  • FDA 510(k) Summary K232879
  • FDA Recalls Z-2913-2026 and Z-1476-2026
  • BSI-Zertifikat ISO/IEC 27001:2022 IS 806759
  • Roche Diagnostics Product Security Advisory
  • Roche press releases on Klinrisk, PathAI, 2026 Annual General Meeting, Genentech–NVIDIA, and FDA clearance for digital pathology

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next